Crystalys Therapeutics develops dotinurad, an oral URAT1 inhibitor for treating gout
Loading investors…
Loading investors…
Activity from announced rounds
Crystalys Therapeutics develops dotinurad, an oral URAT1 inhibitor for treating gout
Provides AI platform for homebuilding design, estimating and construction
Develops antibody therapies to prevent seasonal influenza in high-risk and immunocompromised patients
Builds systems software for AI applications, powering inference and multi-model strategies
Provides consumer fintech platform helping everyday Americans improve their financial lives
Provides a unified IT operations platform for simplifying work
Consumer technology platform redefining how premium goods are produced, priced, and d
Provides AI-native data infrastructure for physical AI systems
Develops novel therapies to reduce the burden of neurodegenerative diseases
Develops bispecific antibody CLD-423 for inflammatory bowel disease